001     135950
005     20240229105047.0
024 7 _ |a 10.1002/ijc.31283
|2 doi
024 7 _ |a pmid:29377173
|2 pmid
024 7 _ |a 0020-7136
|2 ISSN
024 7 _ |a 1097-0215
|2 ISSN
024 7 _ |a altmetric:32416257
|2 altmetric
037 _ _ |a DKFZ-2018-00687
041 _ _ |a eng
082 _ _ |a 610
100 1 _ |a Butt, Julia Anna
|0 P:(DE-He78)31d7c3e829be03400641f80b821ef728
|b 0
|e First author
245 _ _ |a Prospective evaluation of antibody response to Streptococcus gallolyticus and risk of colorectal cancer.
260 _ _ |a Bognor Regis
|c 2018
|b Wiley-Liss
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1680772054_21950
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a The gut microbiome is increasingly implicated in colorectal cancer (CRC) development. A subgroup of patients diagnosed with CRC show high antibody responses to Streptococcus gallolyticus subspecies gallolyticus (SGG). However, it is unclear whether the association is also present pre-diagnostically. We assessed the association of antibody responses to SGG proteins in pre-diagnostic serum samples with CRC risk in a case-control study nested within a prospective cohort. Pre-diagnostic serum samples from 485 first incident CRC cases (mean time between blood draw and diagnosis 3.4 years) and 485 matched controls in the European Prospective Investigation into Nutrition and Cancer (EPIC) study were analyzed for antibody responses to 11 SGG proteins using multiplex serology. Odds ratios (OR) and 95% confidence intervals (CI) were estimated using multivariable conditional logistic regression models. Antibody positivity for any of the 11 SGG proteins was significantly associated with CRC risk with 56% positive controls compared to 63% positive cases (OR: 1.36, 95% CI: 1.04-1.77). Positivity for two or more proteins of a previously identified SGG 6-marker panel with greater CRC-specificity was also observed among 9% of controls compared to 17% of CRC cases, corresponding to a significantly increased CRC risk (OR: 2.17, 95% CI: 1.44-3.27). In this prospective nested case-control study, we observed a positive association between antibody responses to SGG and CRC development in serum samples taken before evident disease onset. Further work is required to establish the possibly etiological significance of these observations and whether SGG serology may be applicable for CRC risk stratification.
536 _ _ |a 316 - Infections and cancer (POF3-316)
|0 G:(DE-HGF)POF3-316
|c POF3-316
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed,
700 1 _ |a Jenab, Mazda
|b 1
700 1 _ |a Willhauck-Fleckenstein, Martina
|0 P:(DE-He78)42f09617805f4c475ccb9a3b943ce28a
|b 2
700 1 _ |a Michel, Angelika
|0 P:(DE-He78)8c4d3a946a1fcde2ded7e17651fd0ed7
|b 3
700 1 _ |a Pawlita, Michael
|0 P:(DE-He78)d99bad949ba3ae93859eedae5ac266da
|b 4
700 1 _ |a Kyrø, Cecilie
|0 0000-0002-9083-8960
|b 5
700 1 _ |a Tjønneland, Anne
|b 6
700 1 _ |a Boutron-Ruault, Marie-Christine
|b 7
700 1 _ |a Carbonnel, Franck
|b 8
700 1 _ |a Severi, Gianluca
|b 9
700 1 _ |a Kaaks, Rudolf
|0 P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a
|b 10
700 1 _ |a Kühn, Tilman
|0 P:(DE-He78)0907a10ba1dc8f53f04907f54f6fdcfe
|b 11
700 1 _ |a Boeing, Heiner
|b 12
700 1 _ |a Trichopoulou, Antonia
|b 13
700 1 _ |a la Vecchia, Carlo
|0 0000-0003-1441-897X
|b 14
700 1 _ |a Karakatsani, Anna
|b 15
700 1 _ |a Panico, Salvatore
|b 16
700 1 _ |a Tumino, Rosario
|b 17
700 1 _ |a Agnoli, Claudia
|b 18
700 1 _ |a Palli, Domenico
|0 0000-0002-5558-2437
|b 19
700 1 _ |a Sacerdote, Carlotta
|0 0000-0002-8008-5096
|b 20
700 1 _ |a Bueno-de-Mesquita, H B As
|b 21
700 1 _ |a Weiderpass, Elisabete
|b 22
700 1 _ |a Sánchez, Maria-José
|b 23
700 1 _ |a Bonet Bonet, Catalina
|b 24
700 1 _ |a Huerta, José María
|b 25
700 1 _ |a Ardanaz, Eva
|b 26
700 1 _ |a Bradbury, Kathryn
|0 0000-0003-3345-7333
|b 27
700 1 _ |a Gunter, Marc
|b 28
700 1 _ |a Murphy, Neil
|0 0000-0003-3347-8249
|b 29
700 1 _ |a Freisling, Heinz
|b 30
700 1 _ |a Riboli, Elio
|b 31
700 1 _ |a Tsilidis, Kostas
|b 32
700 1 _ |a Aune, Dagfinn
|b 33
700 1 _ |a Waterboer, Tim
|0 P:(DE-He78)6b4ebb9791b983b5620c0caaf3468e30
|b 34
|e Last author
700 1 _ |a Hughes, David J
|b 35
773 _ _ |a 10.1002/ijc.31283
|g Vol. 143, no. 2, p. 245 - 252
|0 PERI:(DE-600)1474822-8
|n 2
|p 245 - 252
|t International journal of cancer
|v 143
|y 2018
|x 0020-7136
909 C O |p VDB
|o oai:inrepo02.dkfz.de:135950
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 0
|6 P:(DE-He78)31d7c3e829be03400641f80b821ef728
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 2
|6 P:(DE-He78)42f09617805f4c475ccb9a3b943ce28a
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 3
|6 P:(DE-He78)8c4d3a946a1fcde2ded7e17651fd0ed7
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 4
|6 P:(DE-He78)d99bad949ba3ae93859eedae5ac266da
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 10
|6 P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 11
|6 P:(DE-He78)0907a10ba1dc8f53f04907f54f6fdcfe
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 34
|6 P:(DE-He78)6b4ebb9791b983b5620c0caaf3468e30
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF3-310
|0 G:(DE-HGF)POF3-316
|3 G:(DE-HGF)POF3
|2 G:(DE-HGF)POF3-300
|4 G:(DE-HGF)POF
|v Infections and cancer
|x 0
914 1 _ |y 2018
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b INT J CANCER : 2015
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Thomson Reuters Master Journal List
915 _ _ |a WoS
|0 StatID:(DE-HGF)0110
|2 StatID
|b Science Citation Index
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b INT J CANCER : 2015
920 1 _ |0 I:(DE-He78)F022-20160331
|k F022
|l Infektionen und Krebs-Epidemiologie
|x 0
920 1 _ |0 I:(DE-He78)F020-20160331
|k F020
|l Infektionen und Krebs-Epidemiologie
|x 1
920 1 _ |0 I:(DE-He78)C020-20160331
|k C020
|l C020 Epidemiologie von Krebs
|x 2
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)F022-20160331
980 _ _ |a I:(DE-He78)F020-20160331
980 _ _ |a I:(DE-He78)C020-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21